Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

Chronic spontaneous urticaria places a heavier burden on patients than atopic dermatitis and psoriasis, leading to a worse ...

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...

Apogee Therapeutics has shared positive 16-week results from a mid-stage study of its investigational anti-IL-13 antibody in ...

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color Jun. 07, 2025 6:30 PM ET Regeneron Pharmaceuticals ...

Moderate-to-Severe Atopic Dermatitis: Optimizing Care Across Specialties This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.